Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

NICE likely to reject rimonabant

The National Institute for Health and Clinical Excellence (NICE) are in the process of reviewing Rimonabant for the treatment of overweight and obese adults.

The Appraisal Committee are due to meet again early next year to produce a Final Appraisal Determination but the preliminary recommendations indicate that NICE is unlikely to recommend rimonabant. They have requested additional information from the manufacturer to include evidence from the clinical trials on health outcomes (including cardiovascular risk factors) and evidence on the cost effectiveness of rimonabant compared with diet and exercise alone, as well as the cost effectiveness of rimonabant compared with orlistat and sibutramine.

Action: Clinicians should avoid starting new patients on rimonabant until full guidance is published. Patients who are currently on treatment can continue treatment, within licensed indications, while it continues to be effective.

Thanks to NPCi for the original article

Share 'NICE likely to reject rimonabant' on Email Share 'NICE likely to reject rimonabant' on Delicious Share 'NICE likely to reject rimonabant' on Digg Share 'NICE likely to reject rimonabant' on Facebook Share 'NICE likely to reject rimonabant' on Google+ Share 'NICE likely to reject rimonabant' on reddit Share 'NICE likely to reject rimonabant' on StumbleUpon Share 'NICE likely to reject rimonabant' on Twitter

atomic-wealth

One Comments to “NICE likely to reject rimonabant”

  1. Sanofi Aventis - Acomplia: another nail

    The UK's National Institute for Health and Clinical Excellence (NICE) are in the process of reviewing rimonabant for the treatment of overweight and obese adults.

    The Appraisal Committee are due to meet again early next year to produce a Final Apprai...

    Trackback by Trusted.MD Network — December 12, 2007 #
    Reply

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,320 spam comments.

atomic-wealth
fond-illness
summer